Second malignancies after treatment for Hodgkin's disease

E. Várady, B. Deák, Zs Molnár, A. Rosta, T. Schneider, O. Ésik, S. Eckhardt

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

The occurrence of treatment-related second malignancy following Hodgkin's disease (HD) has now been recognized as a major problem. The purpose of this study was to review our experience with second malignancies in patients treated for Hodgkin's disease, comparing the results with the international literature data. Six hundred and sixty five patients with HD were treated in our department, between 1978 and 1996. Second neoplasm developed in 32 cases (4.8%). Seven secondary hematological malignancies were observed: four acute nonlymphocytic leukemias, two non-Hodgkin's lymphomas and one chronic myeloid leukemia. Among patients with second hematological malignancies, the mean age at diagnosis of HD was 44 years and the mean interval until the development of second malignancy was 6.1 years. Five patients received chemo- and radiotherapy and in two cases chemotherapy was used. Three of the seven patients are alive. Twenty-five patients have had solid tumors, affecting lung (5), breast (3), colon (3), stomach (2), urinary bladder (2), head-and-neck (1), thyroid gland (1), esophagus (1), liver (1), pancreas (1), furthermore, three sarcomas and two malignant melanomas were observed. Their mean age at the diagnosis of HD was 46 years and the mean period of latency was 8.3 years. Chemotherapy was applied to nine patients, 16 patients received both chemo- and radiotherapy. Eleven patients had solid tumors in the region irradiated earlier. Ten out of the 25 patients are alive, three patients' present state is unknown. Since alkylating agents increase the risk of leukemia and irradiation contributes mainly to other malignancies, future treatment protocols should attempt to reduce the most serious consequence of therapy without compromising the survival. It is necessary to investigate the impact of additional risk factors. Careful, lifelong observation is indicated for patients with HD, with special attention given to new clinical signs and symptoms.

Original languageEnglish
Pages (from-to)1275-1281
Number of pages7
JournalLeukemia and Lymphoma
Volume42
Issue number6
DOIs
Publication statusPublished - 2001

Fingerprint

Second Primary Neoplasms
Hodgkin Disease
Therapeutics
Drug Therapy
Hematologic Neoplasms
Radiotherapy
Neoplasms
Alkylating Agents
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Clinical Protocols
Acute Myeloid Leukemia
Sarcoma
Non-Hodgkin's Lymphoma
Esophagus
Signs and Symptoms
Pancreas
Melanoma
Stomach
Thyroid Gland
Colon

Keywords

  • Chemotherapy
  • Hodgkin's disease
  • Radiotherapy
  • Second malignancy

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Várady, E., Deák, B., Molnár, Z., Rosta, A., Schneider, T., Ésik, O., & Eckhardt, S. (2001). Second malignancies after treatment for Hodgkin's disease. Leukemia and Lymphoma, 42(6), 1275-1281. https://doi.org/10.1080/10428190127510

Second malignancies after treatment for Hodgkin's disease. / Várady, E.; Deák, B.; Molnár, Zs; Rosta, A.; Schneider, T.; Ésik, O.; Eckhardt, S.

In: Leukemia and Lymphoma, Vol. 42, No. 6, 2001, p. 1275-1281.

Research output: Contribution to journalArticle

Várady, E, Deák, B, Molnár, Z, Rosta, A, Schneider, T, Ésik, O & Eckhardt, S 2001, 'Second malignancies after treatment for Hodgkin's disease', Leukemia and Lymphoma, vol. 42, no. 6, pp. 1275-1281. https://doi.org/10.1080/10428190127510
Várady E, Deák B, Molnár Z, Rosta A, Schneider T, Ésik O et al. Second malignancies after treatment for Hodgkin's disease. Leukemia and Lymphoma. 2001;42(6):1275-1281. https://doi.org/10.1080/10428190127510
Várady, E. ; Deák, B. ; Molnár, Zs ; Rosta, A. ; Schneider, T. ; Ésik, O. ; Eckhardt, S. / Second malignancies after treatment for Hodgkin's disease. In: Leukemia and Lymphoma. 2001 ; Vol. 42, No. 6. pp. 1275-1281.
@article{fb992ec1d7c346a38ff33f363a461660,
title = "Second malignancies after treatment for Hodgkin's disease",
abstract = "The occurrence of treatment-related second malignancy following Hodgkin's disease (HD) has now been recognized as a major problem. The purpose of this study was to review our experience with second malignancies in patients treated for Hodgkin's disease, comparing the results with the international literature data. Six hundred and sixty five patients with HD were treated in our department, between 1978 and 1996. Second neoplasm developed in 32 cases (4.8{\%}). Seven secondary hematological malignancies were observed: four acute nonlymphocytic leukemias, two non-Hodgkin's lymphomas and one chronic myeloid leukemia. Among patients with second hematological malignancies, the mean age at diagnosis of HD was 44 years and the mean interval until the development of second malignancy was 6.1 years. Five patients received chemo- and radiotherapy and in two cases chemotherapy was used. Three of the seven patients are alive. Twenty-five patients have had solid tumors, affecting lung (5), breast (3), colon (3), stomach (2), urinary bladder (2), head-and-neck (1), thyroid gland (1), esophagus (1), liver (1), pancreas (1), furthermore, three sarcomas and two malignant melanomas were observed. Their mean age at the diagnosis of HD was 46 years and the mean period of latency was 8.3 years. Chemotherapy was applied to nine patients, 16 patients received both chemo- and radiotherapy. Eleven patients had solid tumors in the region irradiated earlier. Ten out of the 25 patients are alive, three patients' present state is unknown. Since alkylating agents increase the risk of leukemia and irradiation contributes mainly to other malignancies, future treatment protocols should attempt to reduce the most serious consequence of therapy without compromising the survival. It is necessary to investigate the impact of additional risk factors. Careful, lifelong observation is indicated for patients with HD, with special attention given to new clinical signs and symptoms.",
keywords = "Chemotherapy, Hodgkin's disease, Radiotherapy, Second malignancy",
author = "E. V{\'a}rady and B. De{\'a}k and Zs Moln{\'a}r and A. Rosta and T. Schneider and O. {\'E}sik and S. Eckhardt",
year = "2001",
doi = "10.1080/10428190127510",
language = "English",
volume = "42",
pages = "1275--1281",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "6",

}

TY - JOUR

T1 - Second malignancies after treatment for Hodgkin's disease

AU - Várady, E.

AU - Deák, B.

AU - Molnár, Zs

AU - Rosta, A.

AU - Schneider, T.

AU - Ésik, O.

AU - Eckhardt, S.

PY - 2001

Y1 - 2001

N2 - The occurrence of treatment-related second malignancy following Hodgkin's disease (HD) has now been recognized as a major problem. The purpose of this study was to review our experience with second malignancies in patients treated for Hodgkin's disease, comparing the results with the international literature data. Six hundred and sixty five patients with HD were treated in our department, between 1978 and 1996. Second neoplasm developed in 32 cases (4.8%). Seven secondary hematological malignancies were observed: four acute nonlymphocytic leukemias, two non-Hodgkin's lymphomas and one chronic myeloid leukemia. Among patients with second hematological malignancies, the mean age at diagnosis of HD was 44 years and the mean interval until the development of second malignancy was 6.1 years. Five patients received chemo- and radiotherapy and in two cases chemotherapy was used. Three of the seven patients are alive. Twenty-five patients have had solid tumors, affecting lung (5), breast (3), colon (3), stomach (2), urinary bladder (2), head-and-neck (1), thyroid gland (1), esophagus (1), liver (1), pancreas (1), furthermore, three sarcomas and two malignant melanomas were observed. Their mean age at the diagnosis of HD was 46 years and the mean period of latency was 8.3 years. Chemotherapy was applied to nine patients, 16 patients received both chemo- and radiotherapy. Eleven patients had solid tumors in the region irradiated earlier. Ten out of the 25 patients are alive, three patients' present state is unknown. Since alkylating agents increase the risk of leukemia and irradiation contributes mainly to other malignancies, future treatment protocols should attempt to reduce the most serious consequence of therapy without compromising the survival. It is necessary to investigate the impact of additional risk factors. Careful, lifelong observation is indicated for patients with HD, with special attention given to new clinical signs and symptoms.

AB - The occurrence of treatment-related second malignancy following Hodgkin's disease (HD) has now been recognized as a major problem. The purpose of this study was to review our experience with second malignancies in patients treated for Hodgkin's disease, comparing the results with the international literature data. Six hundred and sixty five patients with HD were treated in our department, between 1978 and 1996. Second neoplasm developed in 32 cases (4.8%). Seven secondary hematological malignancies were observed: four acute nonlymphocytic leukemias, two non-Hodgkin's lymphomas and one chronic myeloid leukemia. Among patients with second hematological malignancies, the mean age at diagnosis of HD was 44 years and the mean interval until the development of second malignancy was 6.1 years. Five patients received chemo- and radiotherapy and in two cases chemotherapy was used. Three of the seven patients are alive. Twenty-five patients have had solid tumors, affecting lung (5), breast (3), colon (3), stomach (2), urinary bladder (2), head-and-neck (1), thyroid gland (1), esophagus (1), liver (1), pancreas (1), furthermore, three sarcomas and two malignant melanomas were observed. Their mean age at the diagnosis of HD was 46 years and the mean period of latency was 8.3 years. Chemotherapy was applied to nine patients, 16 patients received both chemo- and radiotherapy. Eleven patients had solid tumors in the region irradiated earlier. Ten out of the 25 patients are alive, three patients' present state is unknown. Since alkylating agents increase the risk of leukemia and irradiation contributes mainly to other malignancies, future treatment protocols should attempt to reduce the most serious consequence of therapy without compromising the survival. It is necessary to investigate the impact of additional risk factors. Careful, lifelong observation is indicated for patients with HD, with special attention given to new clinical signs and symptoms.

KW - Chemotherapy

KW - Hodgkin's disease

KW - Radiotherapy

KW - Second malignancy

UR - http://www.scopus.com/inward/record.url?scp=0035697022&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035697022&partnerID=8YFLogxK

U2 - 10.1080/10428190127510

DO - 10.1080/10428190127510

M3 - Article

C2 - 11911408

AN - SCOPUS:0035697022

VL - 42

SP - 1275

EP - 1281

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 6

ER -